Mitchell S Buckley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4016852/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fish Oil Interaction with Warfarin. Annals of Pharmacotherapy, 2004, 38, 50-53.	1.9	107
2	A critical evaluation of clinical decision support for the detection of drug–drug interactions. Expert Opinion on Drug Safety, 2011, 10, 871-882.	2.4	99
3	Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. Critical Care Medicine, 2010, 38, S253-S264.	0.9	97
4	Direct observation approach for detecting medication errors and adverse drug events in a pediatric intensive care unit*. Pediatric Critical Care Medicine, 2007, 8, 145-152.	0.5	94
5	Impact of a Clinical Pharmacy Admission Medication Reconciliation Program on Medication Errors in "High-Risk―Patients. Annals of Pharmacotherapy, 2013, 47, 1599-1610.	1.9	83
6	Clinical Practice Guideline: Safe Medication Use in the ICU. Critical Care Medicine, 2017, 45, e877-e915.	0.9	75
7	Stress Ulcer Prophylaxis. Critical Care Medicine, 2016, 44, 1395-1405.	0.9	70
8	A Review of Inhaled Nitric Oxide and Aerosolized Epoprostenol in Acute Lung Injury or Acute Respiratory Distress Syndrome. Pharmacotherapy, 2014, 34, 279-290.	2.6	64
9	Impact of a Clinical Pharmacist Stress Ulcer Prophylaxis Management Program on Inappropriate Use in Hospitalized Patients. American Journal of Medicine, 2015, 128, 905-913.	1.5	63
10	An evidence based systematic review of remifentanil associated opioid-induced hyperalgesia. Expert Opinion on Drug Safety, 2014, 13, 587-603.	2.4	42
11	Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit. Journal of Critical Care, 2018, 48, 32-38.	2.2	42
12	Interpatient Variability in Dexmedetomidine Response: A Survey of the Literature. Scientific World Journal, The, 2014, 2014, 1-12.	2.1	38
13	Evaluation of Potential Drug–Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis. Drug Safety, 2019, 42, 1035-1044.	3.2	36
14	Inhaled Epoprostenol for the Treatment of Pulmonary Arterial Hypertension in Critically III Adults. Pharmacotherapy, 2010, 30, 728-740.	2.6	33
15	A Multicenter Evaluation of Off-Label Medication Use and Associated Adverse Drug Reactions in Adult Medical ICUs. Critical Care Medicine, 2015, 43, 1612-1621.	0.9	30
16	Characterizing Critical Care Pharmacy Services Across the United States. , 2021, 3, e0323.		30
17	Optimization of critical care pharmacy clinical services: A gap analysis approach. American Journal of Health-System Pharmacy, 2021, 78, 2077-2085.	1.0	30
18	Drug Class Combination–Associated Acute Kidney Injury. Annals of Pharmacotherapy, 2016, 50, 953-972.	1.9	29

MITCHELL S BUCKLEY

#	Article	IF	CITATIONS
19	Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy. Drug, Healthcare and Patient Safety, 2010, 2, 151.	2.5	22
20	Catecholamine Vasopressor Support Sparing Strategies in Vasodilatory Shock. Pharmacotherapy, 2019, 39, 382-398.	2.6	21
21	Examination of critical care pharmacist work activities and burnout. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 554-569.	1.0	17
22	Combination therapy in the management of pulmonary arterial hypertension. International Journal of Clinical Practice, 2013, 67, 13-23.	1.7	16
23	Evaluation of an Automated Surveillance System Using Trigger Alerts to Prevent Adverse Drug Events in the Intensive Care Unit and General Ward. Drug Safety, 2015, 38, 311-317.	3.2	16
24	Correlation of Free and Total Phenytoin Serum Concentrations in Critically III Patients. Annals of Pharmacotherapy, 2016, 50, 276-281.	1.9	16
25	Clinical Pharmacist–Led Impact on Inappropriate Albumin Use and Costs in the Critically III. Annals of Pharmacotherapy, 2020, 54, 105-112.	1.9	16
26	Adverse Hemodynamic Events Associated With Concomitant Dexmedetomidine and Propofol for Sedation in Mechanically Ventilated ICU Patients. Journal of Intensive Care Medicine, 2020, 35, 1536-1545.	2.8	16
27	Pharmacokinetic evaluation of ambrisentan. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 371-380.	3.3	15
28	Conivaptan for Treatment of Hyponatremia in Neurologic and Neurosurgical Adults. Annals of Pharmacotherapy, 2013, 47, 1194-1200.	1.9	15
29	Comparison of Fixed-Dose Inhaled Epoprostenol and Inhaled Nitric Oxide for Acute Respiratory Distress Syndrome in Critically III Adults. Journal of Intensive Care Medicine, 2021, 36, 466-476.	2.8	13
30	A Real-World, Multicenter Assessment of Drugs Requiring Weight-Based Calculations in Overweight, Adult Critically III Patients. Scientific World Journal, The, 2013, 2013, 1-9.	2.1	12
31	Action Plan for Successful Implementation of Optimal ICU Pharmacist Activities: Next Steps for the Critical Care Pharmacist Position Paper. Critical Care Medicine, 2021, 49, e199-e200.	0.9	12
32	Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study. Journal of Critical Care, 2022, 67, 134-140.	2.2	11
33	Clinical and Economic Evaluation of an Evidence-Based Institutional Epoetin-Utilization Management Program. Clinical Therapeutics, 2013, 35, 294-302.	2.5	10
34	Dexmedetomidine for Facilitating Mechanical Ventilation Extubation in Difficult-to-Wean ICU Patients: Systematic Review and Meta-Analysis of Clinical Trials. Journal of Intensive Care Medicine, 2021, 36, 925-936.	2.8	10
35	Development and application of quality measures of clinical pharmacist services provided in inpatient/acute care settings. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1601-1617.	1.0	10
36	Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evidence, 2014, 9, 71.	4.7	9

MITCHELL S BUCKLEY

#	Article	IF	CITATIONS
37	Trigger alerts associated with laboratory abnormalities on identifying potentially preventable adverse drug events in the intensive care unit and general ward. Therapeutic Advances in Drug Safety, 2018, 9, 207-217.	2.4	8
38	Moderate to Severe Acute Respiratory Distress Syndrome Management Strategies: A Narrative Review. Journal of Pharmacy Practice, 2019, 32, 347-360.	1.0	8
39	Clinical Pharmacist–Led Impact on Inappropriate Albumin Utilization and Associated Costs in General Ward Patients. Annals of Pharmacotherapy, 2021, 55, 44-51.	1.9	7
40	Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit. Annals of Pharmacotherapy, 2017, 51, 529-542.	1.9	5
41	Concomitant vasopressin and hydrocortisone therapy on short-term hemodynamic effects and vasopressor requirements in refractory septic shock. Journal of Critical Care, 2017, 42, 6-11.	2.2	3
42	Executive Summary: Clinical Practice Guideline: Safe Medication Use in the ICU. Critical Care Medicine, 2017, 45, 1546-1551.	0.9	3
43	The SUP-ICU Trial: Does It Confirm or Condemn the Practice of Stress Ulcer Prophylaxis?. Hospital Pharmacy, 2020, 55, 96-101.	1.0	3
44	Apparent lack of cross-reactivity for infusion-related reactions between two forms of lipid-based amphotericin B. American Journal of Health-System Pharmacy, 2013, 70, 1047-1051.	1.0	1
45	Hyperoncotic Albumin Reduces Net Fluid Loss Associated With Hemodialysis. Hospital Pharmacy, 2020, 55, 130-134.	1.0	1
46	Benefits of Patient/Caregiver Engagement in Adverse Drug Reaction Reporting Compared With Other Sources of Reporting in the Inpatient Setting: A Systematic Review. Journal of Patient Safety, 2021, 17, e765-e772.	1.7	1
47	Authors' Reply to Uysal and Colleagues' Comment on: "Evaluation of Potential Drug–Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis― Drug Safety, 2020, 43, 195-196.	3.2	1
48	Incidence of Hypotension Associated With Two Different Vasopressin Discontinuation Strategies in the Recovery Phase of Septic Shock. Journal of Pharmacy Practice, 2023, 36, 830-838.	1.0	1
49	Reply. Annals of Pharmacotherapy, 2016, 50, 520-520.	1.9	0

50 Hypertonic Saline, Electrolytes, and Insulin. , 2011, , 139-151.

0